Encompass Health vs Ensign
EHC and ENSG side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EHC and ENSG compare
Encompass Health is the larger company, worth 1.2 times as much as Ensign ($13.0B against $10.9B).
On earnings, Encompass Health is cheaper: it trades at 21.4× trailing earnings, against 29.2× for Ensign.
Ensign grew revenue faster over the last twelve months (18.9% versus 9.5% for Encompass Health).
Encompass Health keeps more of each dollar of sales as profit, with a net margin of 10.0% compared with 6.9% at Ensign.
Both pay dividends: Encompass Health yields 0.59% and Ensign 0.14%.
Ensign scores higher on the StockData Score (19 against 17 for Encompass Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EHC | ENSG |
|---|---|---|
| Size and price | ||
| Market cap | $13.0B | $10.9B |
| Share price | $131.49 | $186.32 |
| Change, 1 year | 4.1% | 0.37% |
| Change, 5 years | 102% | 124% |
| Beta (5Y) | 0.70 | 0.46 |
| Employees | 42K | 46K |
| StockData Score | ||
| Total score | 17 | 19 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 | 5 (better) |
| Performance score | 5 | 6 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 21.4× (better) | 29.2× |
| P/S | 2.1× | 2.0× (better) |
| P/B | 5.0× | 4.4× (better) |
| EV/EBITDA | 10.9× (better) | 18.4× |
| P/FCF | 31.4× | – |
| PEG | 0.79 (better) | 2.10 |
| FCF yield | 3.2% | – |
| Fair value | $123.38 | $151.76 |
| Margin of safety | −6.6% (better) | −22.8% |
| Growth | ||
| Revenue growth (TTM) | 9.5% | 18.9% (better) |
| Revenue growth, 5Y average | 10.7% | 16.1% (better) |
| Net income growth (TTM) | 18.8% (better) | 17.3% |
| EPS growth (TTM) | 20.2% (better) | 15.8% |
| EPS growth, 5Y average | 14.2% (better) | 13.8% |
| Profitability | ||
| Gross margin | – | 20.7% |
| Operating margin | – | 8.5% |
| Net margin | 10.0% (better) | 6.9% |
| FCF margin | 6.7% | – |
| Return on equity | 25.5% (better) | 17.0% |
| Return on invested capital | – | 17.7% |
| Financial health | ||
| Debt / equity | 1.01 | 0.06 (better) |
| Net debt / EBITDA | 1.68 (better) | −0.31 |
| Interest coverage | – | 60.0× |
| Current ratio | 1.19 | 1.21 (better) |
| Altman Z-score | 2.81 | 3.71 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.59% (better) | 0.14% |
| Payout ratio | 12.1% | 3.9% |
| Years of dividend growth | 2 | 15 (better) |
| Dividend growth, 5Y average | −8.5% | 4.5% (better) |
| Buyback yield | 1.9% (better) | 0.37% |
| Shareholder yield | 2.5% (better) | 0.51% |
| Ownership | ||
| Held by institutions | 97.0% | 90.6% |
| Held by insiders | 1.0% | 3.6% |
| Insider net buying, 12 months | −$47.8M | −$13.6M (better) |
| Short interest, % of float | 3.6% | 2.6% |
Go deeper
- EHC stock overview
- EHC income statement
- EHC valuation and score
- ENSG stock overview
- ENSG income statement
- ENSG valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.